Hereditary nonpolyposis colorectal cancer secondary prevention

Hereditary Nonpolyposis Colorectal Cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hereditary nonpolyposis colorectal cancer secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hereditary nonpolyposis colorectal cancer secondary prevention
CDC on Hereditary nonpolyposis colorectal cancer secondary prevention
Hereditary nonpolyposis colorectal cancer secondary prevention in the news
Blogs on Hereditary nonpolyposis colorectal cancer secondary prevention
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy.

Secondary prevention

Recent studies demonstrate a reduced incidence in hereditary nonpolyposis colorectal cancer patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile. These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA).

Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:

• Colonoscopy between 25-35 years, every 2 years.

• Pelvic exam, transvaginal ultrasound and CA-125 between 25-35 years, every year.

• Endometrial biopsy, in relation to clinical symptoms.

• Urine cytology (families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis, between 25-35 years every year)

References

Template:WikiDoc Sources